FDA approves PFE’s Besponsa (inotuzumab ozogamicin) for ALL subtype: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm572131.htm Besponsa is an antibody-drug conjugate that was awarded BTD in 2015.